Coronavirus Live Count Map India
remove_red_eye 631 Views
Coronavirus Live Count Map World
Coronavirus FAQ PDF
Patients with non-exudative (dry) age-related macular degeneration (dAMD) obtained meaningful vision improvement at 6 months with a drug targeting oxidative stress versus sham treatment in a phase II clinical trial.
Results showed that 12 of 25 patients improved by ≥8 ETDRS letters in best corrected visual acuity (BCVA) at 28 weeks with risuteganib as compared with one of 14 patients in the sham group. The drug was well tolerated, David S. Boyer, MD, of Retina-Vitreous Associates Medical Group in Los Angeles, reported at the American Academy of Ophthalmology meeting.